AnnJi Pharmaceutical News
Dedicated to New Drug Development in Dermatology & Neurology
Press Release
AnnJi to Attend BIO Asia–Taiwan 2022 Company Presentation Session and BIO One-on-One PartneringTM
AnnJi will be attending BIO Asia–Taiwan 2022, July 27-31, to meet with potential pharmaceutical partners and investors regarding AnnJi’s programs in dermatology and neurology. Dr. K. Karen Lin, the Director of Business Development, is going to present company’s clinical profiles on site at 16:15, July 27 (https://bioasiataiwan.com/en/program/detail/46). AnnJi welcome an opportunity to meet with you
Dr. Wendy Huang, AnnJi’s Chair and CEO, gave a lecture at Taiwania Young Entrepreneurs Academy About New Opportunities for Small Molecule Drug Development
On 14th, May 2022, Taiwania Capital and Development Center for Biotechnology (DCB) invited Dr. Wendy Huang, Chair and CEO of AnnJi Pharmaceutical (AnnJi), to give a lecture on “New Opportunities for Small Molecule Drug Development”. Dr. Wendy Huang gave an overview about the recent AI technologies in aiding new drug design, the novel drug delivery
AnnJi Pharmaceutical’s HDAC6 selective inhibitor received “Grass Roots” Support Program Award sponsored by Boehringer Ingelheim, Taiwan
AnnJi Pharmaceutical (AnnJi) was awarded the Boehringer Ingelheim “Grass Roots”Support Program for its new drug development project, AJ303. There are six 6 awardees chosen from 169 applicants, and AnnJi and AJ303 stands out as the only new drug development companies (Source: Boehringer Ingelheim_Taiwan ; News Report: Taipei Times). “Grass Roots” Support Program is a worldwide
AnnJi Pharmaceutical Sponsors “The Great Road Trip”, a Charitable Fundraising Event on Behalf of Kennedy’s Disease Patients
AnnJi Pharmaceutical (AnnJi) donated to the charitable fundraising activity, “The Great Road Trip”, organized by Kennedy’s Disease-UK (KD-UK) and the Kennedy’s Disease Association (KDA) in the US, to raise awareness of Kennedy’s Disease and to bring funds for research programs. This charity fundraiser was initiated by two former British Royal Navy pilots, both patients of
Dr. Wendy Huang, Chair and CEO of AnnJi Pharmaceutical Company Spoke on Consideration and Strategy of Candidates Selection in New Drug Development
On 9th, Dec. 2021, Clarivate held a webinar with the main theme “Patient demand is trending the candidate selection for new drug innovation and market entry strategies”, and invited Dr. Wendy Huang, Chair and CEO of AnnJi Pharmaceutical (AnnJi), as the keynote speaker to share her experiences. Dr. Wendy Huang took the histone deacetylase 6
Dr. Michael Chan to Present AJ201 Preclinical Research and Phase 1 Study Results at 2021 SBMA Research Conference Sponsored by Kennedy’s Disease Association (KDA)
The Annual International SBMA Research Conference sponsored by Kennedy’s Disease Association (KDA) will be held online during October 22-25, 2021. Dr. Michael Y Chan, Ph.D., VP of the Research and Translational Medicine in AnnJi Pharmaceutical Co., Ltd. (AnnJi), is invited to present AnnJi’s research and clinical development plan of AJ201 for the treatment of SBMA.
Taiwan’s leading new drug developer in dermatology & neurology
Translation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept
